Posted by Michael Wonder on 28 Jan 2025
Beacon Therapeutics granted FDA regenerative medicine advanced therapy designation for laru-zova (AGTC-501)
28 January 2025 - Recognises preliminary clinical evidence from the Phase 2 DAWN and SKYLINE trials of laru-zova in X-linked retinitis pigmentosa.
Beacon Therapeutics today announced that the US FDA has granted regenerative medicine advanced therapy designation laruparetigene zovaparvovec (laru-zova) for the treatment of X-linked retinitis pigmentosa.
